AXSM – Axsome Therapeutics, Inc.
Float Short %
8.2
Margin Of Safety %
Put/Call OI Ratio
0.78
EPS Next Q Diff
0.33
EPS Last/This Y
2.13
EPS This/Next Y
4.12
Price
147.56
Target Price
179.74
Analyst Recom
1.05
Performance Q
17.41
Relative Volume
1.19
Beta
0.46
Ticker: AXSM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | AXSM | 137.89 | 0.69 | 0.09 | 21281 |
| 2025-11-11 | AXSM | 139.78 | 0.69 | 4.02 | 21294 |
| 2025-11-12 | AXSM | 140.9 | 0.70 | 0.24 | 21269 |
| 2025-11-13 | AXSM | 136.56 | 0.69 | 0.03 | 21546 |
| 2025-11-14 | AXSM | 139.75 | 0.68 | 0.08 | 21800 |
| 2025-11-17 | AXSM | 145.39 | 0.66 | 0.29 | 22267 |
| 2025-11-18 | AXSM | 147.41 | 0.66 | 1.75 | 22738 |
| 2025-11-19 | AXSM | 146.76 | 0.69 | 0.38 | 23438 |
| 2025-11-20 | AXSM | 143.25 | 0.69 | 0.51 | 23705 |
| 2025-11-21 | AXSM | 149.44 | 0.69 | 0.29 | 23860 |
| 2025-11-24 | AXSM | 151.27 | 0.72 | 0.09 | 21422 |
| 2025-11-25 | AXSM | 150.2 | 0.70 | 0.07 | 21739 |
| 2025-11-26 | AXSM | 150.85 | 0.69 | 0.08 | 21958 |
| 2025-12-01 | AXSM | 149.19 | 0.68 | 0.53 | 22123 |
| 2025-12-02 | AXSM | 141.95 | 0.69 | 4.59 | 22020 |
| 2025-12-03 | AXSM | 147.77 | 0.70 | 5.08 | 22269 |
| 2025-12-04 | AXSM | 148.1 | 0.76 | 2.16 | 23023 |
| 2025-12-05 | AXSM | 149.13 | 0.78 | 1.68 | 23337 |
| 2025-12-08 | AXSM | 147.76 | 0.78 | 0.16 | 23392 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | AXSM | 137.80 | 37.5 | 284.9 | -4.28 |
| 2025-11-11 | AXSM | 139.61 | 42.6 | 285.9 | -3.95 |
| 2025-11-12 | AXSM | 140.88 | 42.6 | 285.6 | -3.95 |
| 2025-11-13 | AXSM | 137.47 | 41.3 | 283.5 | -3.86 |
| 2025-11-14 | AXSM | 139.69 | 41.3 | 286.1 | -3.86 |
| 2025-11-17 | AXSM | 145.42 | 47.3 | 287.7 | -3.84 |
| 2025-11-18 | AXSM | 147.40 | 47.3 | 285.9 | -3.86 |
| 2025-11-19 | AXSM | 146.77 | 47.3 | 284.8 | -3.86 |
| 2025-11-20 | AXSM | 143.16 | 48.9 | 283.5 | -3.86 |
| 2025-11-21 | AXSM | 149.41 | 48.9 | 287.7 | -3.86 |
| 2025-11-24 | AXSM | 151.22 | 48.9 | 285.8 | -3.86 |
| 2025-11-25 | AXSM | 150.36 | 48.9 | 284.7 | -3.86 |
| 2025-11-26 | AXSM | 151.00 | 48.9 | 285.3 | -3.86 |
| 2025-12-01 | AXSM | 149.11 | 48.9 | 284.1 | -3.86 |
| 2025-12-02 | AXSM | 142.09 | 48.9 | 282.1 | -3.86 |
| 2025-12-03 | AXSM | 147.81 | 48.9 | 287.6 | -3.86 |
| 2025-12-04 | AXSM | 148.01 | 48.9 | 285.1 | -3.86 |
| 2025-12-05 | AXSM | 149.22 | 48.9 | 285.6 | -3.86 |
| 2025-12-08 | AXSM | 147.56 | 48.9 | - | -3.86 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | AXSM | -5.95 | 0.25 | 8.26 |
| 2025-11-11 | AXSM | -5.95 | 0.25 | 8.26 |
| 2025-11-12 | AXSM | -5.95 | 0.25 | 8.67 |
| 2025-11-13 | AXSM | -5.95 | 0.25 | 8.67 |
| 2025-11-14 | AXSM | -5.95 | 0.25 | 8.63 |
| 2025-11-17 | AXSM | -6.08 | 2.61 | 8.63 |
| 2025-11-18 | AXSM | -6.07 | 2.61 | 8.63 |
| 2025-11-19 | AXSM | -6.07 | 2.61 | 8.63 |
| 2025-11-20 | AXSM | -6.08 | 2.61 | 8.63 |
| 2025-11-21 | AXSM | -6.05 | 2.61 | 8.71 |
| 2025-11-24 | AXSM | -5.79 | -0.32 | 8.71 |
| 2025-11-25 | AXSM | -5.79 | -0.32 | 8.71 |
| 2025-11-26 | AXSM | -5.79 | -0.32 | 8.20 |
| 2025-12-01 | AXSM | -5.31 | -0.27 | 8.20 |
| 2025-12-02 | AXSM | -5.31 | -0.27 | 8.20 |
| 2025-12-03 | AXSM | -5.31 | -0.27 | 8.20 |
| 2025-12-04 | AXSM | -5.31 | -0.27 | 8.20 |
| 2025-12-05 | AXSM | -6.10 | -0.27 | 8.20 |
| 2025-12-08 | AXSM | -6.10 | -0.32 | 8.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.94
Avg. EPS Est. Current Quarter
-0.79
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-6.1
Institutional Transactions
-0.32
Beta
0.46
Average Sales Estimate Current Quarter
187
Average Sales Estimate Next Quarter
191
Fair Value
Quality Score
30
Growth Score
39
Sentiment Score
31
Actual DrawDown %
3.5
Max Drawdown 5-Year %
-77
Target Price
179.74
P/E
Forward P/E
368.87
PEG
P/S
13.25
P/B
100.69
P/Free Cash Flow
EPS
-4.67
Average EPS Est. Cur. Y
-3.86
EPS Next Y. (Est.)
0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-40.89
Relative Volume
1.19
Return on Equity vs Sector %
-338.2
Return on Equity vs Industry %
-323.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
Axsome Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 816
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
stock quote shares AXSM – Axsome Therapeutics, Inc. Stock Price stock today
news today AXSM – Axsome Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AXSM – Axsome Therapeutics, Inc. yahoo finance google finance
stock history AXSM – Axsome Therapeutics, Inc. invest stock market
stock prices AXSM premarket after hours
ticker AXSM fair value insiders trading